



THE UNIVERSITY OF  
WESTERN AUSTRALIA

*Achieve International Excellence*

## School of Pathology and Laboratory Medicine



## CURRICULUM VITAE of Dr. Jiake Xu ([jiake.xu@uwa.edu.au](mailto:jiake.xu@uwa.edu.au))

Name: Jiake Xu

### Academic qualifications:

1980.9-1985.7 B. Med Guangzhou Medical University, Guangzhou, China  
1991.2-1994.12 Ph.D School of Pathology and Laboratory Medicine, The University of Western Australia, Australia

### Previous academic positions held:

1994.12-1998.5	Postdoctoral Fellow	School of Medicine, Stanford University
1998.5-2001.2	Research Associate	School of Surgery and Pathology, The University of Western Australia, Australia
2001.3-2003.3	Research Follow/Head of Lab	School of Surgery and Pathology, The University of Western Australia, Australia
2003.3-2007.3	Senior Lecturer/Head of Lab	School of Surgery and Pathology, The University of Western Australia, Australia
2007.3-2009.3	Asso. Professor/Head of Lab	School of Surgery and Pathology, The University of Western Australia, Australia
2009.3-2011.3	Professor//Head of Lab	School of Surgery and Pathology, The University of Western Australia, Australia

### Present academic position:

2011.3-	Winthrop Professor /Head of Lab	School of Pathology and Laboratory Medicine, The University of Western Australia, Australia
2014.8-	University Fellow	Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University

### Previous relevant research work: (<http://www.uwa.edu.au/people/jiake.xu>)

Technical expertise Osteoimmunology, osteolysis, and mechanisms of bone resorption  
Research area RANKL signalling transduction pathways and transcription program  
Screening of natural compounds for the treatment of osteoporosis  
Deciphering the molecular basis of musculoskeletal diseases using ENU-induced mutant mice  
Osteoclast and osteoblast intercellular communication

**Publication Records:** 102 SCI Papers, 7 Book Chapters, >200 Conference abstracts.

### Ten Representative publications in the past ten years

1. Yip KHM, Zheng HM, Feng HT, Steer JH, Joyce DA, **Xu J** (2004) Sesquiterpene lactone parthenolide blocks lipopolysaccharide induced osteolysis via the suppression of NF- $\kappa$ B. *J Bone Miner Res* 19(11):1905-16.
2. Yip KHM, Zheng MH, Steer JH, Giardina TM, Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA, **Xu J** (2005) Thapsigargin (TG) modulates osteoclastogenesis via the regulation of RANKL-induced signaling pathways and reactive oxygen species production. *J Bone Miner Res* 8:1462-71.
3. S L Rea (nee Morgan), Walsh JP, Ward L, Ward BK, Kent GN, **Xu J**, Ratajczak T. (2006) A Novel Mutation (K378X) in the Sequestosome 1 Gene Associated with Increased NF- $\kappa$ B signalling and Paget's disease of bone with a Severe Phenotype. *J Bone Miner Res*. 21:1136-45.
4. Feng H, Cheng T, Pavlos N, Yip KH, Seeber R, Eidne K, Zheng MH, **Xu J** (2008) Cytoplasmic terminus of a vacuolar type proton pump accessory subunit Ac45 is required for proper interaction with V0 domain subunits and efficient osteoclastic bone resorption. *J Biol Chem*. 9;283(19):13194-204.
5. Rea SL, Walsh JP, Ward L, Magno AL, Ward BK, Shaw B, Layfield R, Kent GN, **Xu J**, Ratajczak T. (2009) Sequestosome 1 Mutations in Paget's Disease of Bone in Australia: Prevalence, Genotype/Phenotype Correlation and a Novel Non-UBA Domain Mutation (P364S) Associated with Increased NF- $\kappa$ B Signaling Without Loss of Ubiquitin-Binding. *J Bone Miner Res*. 24(7):1216-23.
6. Feng H, Cheng T, Steer JH, Joyce DA, Pavlos NJ, Leong C, Kular J, Liu J, Feng X, Zheng MH, **Xu J**. (2009) MEF2 and MITF cooperate with NFATC1 to transactivate the V-ATPase D2 promoter during RANKL-induced osteoclastogenesis. *J Biol Chem*. 284(21):14667-76.
7. Chim SM, Qin A, Tickner J, Pavlos NJ, Davey T, Wang H, Guo Y, Zheng MH, **Xu J**. (2011) EGFL6 promotes endothelial cell migration and angiogenesis through the activation of ERK. *J Biol Chem*. 286(25):22035-46.
8. Pavlos NJ, Cheng T, Qin A, Feng H, Cheng T, Jahn R, Zheng MH, **Xu J**. (2011) Tctex-1, a novel interaction partner of Rab3D, is required for osteoclastic bone resorption. *Mol. Cell. Biol*. 31(7):1551-64.
9. Guo J, Ren F, Wang Y, Li S, Gao Z, Wang X, Ning H, Wu J, Li Y, Wang Z, Chim SM, **Xu J**, Chang Z. (2012) miR-764-5p promotes osteoblast differentiation through inhibition of CHIP/STUB1 expression. *J Bone Miner Res*. 27(7):1607-18.

10. Rea SL, Walsh JP, Layfield R, Ratajczak T, Xu J. (2013) New insights into the role of Sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone. *Endocrine Reviews*. 34(4):501-24.